Development↦Quality and Risk↦Risk Communication↦Strategy
Was betrifft es? Warum ist das wichtig?
The risk strategy of a study provides structured guidance on how to manage study risks. Persons involved in risk management activities or affected by risk control-measures should:
- Receive ongoing information to its effectiveness including potential adaptations
- Provide ongoing relevant feedback to the risk management team and/or SP-INV
This approach will
- Facilitate risk reviews
- Insure continual improvement
- Enable to learn from experience (e.g. lessons learned)
- Promote transparency and support to the risk-based QMS of the study
Communication methods may include regular updates between SP-INV, Site-INV and study staff during team meetings, newsletter from SP-INV, ongoing study trainings.
Mehr
Example of an established risk management process: Safety reporting at a study site for clinical trials with Investigational Medicinal Product (IMP)
Required process: All SAEs must be reported to SP-INV within 24 hours (except events that are exempt according to the study protocol).
Risk management prior to study conduct
- Risk identification: SAE reporting is not done or not within required timeline (24 hr)
- Risk evaluation: is likely to occur and will have serious impact on participant safety
- Risk prioritisation: High priority due to safety risks for study participants
Implemented risk control-measures
- Clearly defined SAE reporting procedures described in a SOP or WI
- Two monitoring visits will be conducted during study conduct in order to assess compliance with SAE reporting procedures
Riskdocumentation and communication
- The Site-INV documents any SAE non-compliance in a study deviation log
- Applicable study staff is trained on applicable SOPs and/or WIs regarding SAE reporting procedures
QC and monitoring visit during study conduct
- Monitoring findings: SAE reporting timeline to SP-INV was delayed in 2 instances
- Root cause analysis: reporting responsibilities were unclear
Implemented risk control-measures and risk communication
- SAE reporting responsibilities are delegated by the Site.-INV to one key staff member (e.g. documented on the site delegation-log)
- Staff is trained on adapted safety reporting measures
Was muss ich befolgen?
As a SP-INV and in alignment with the risk prevention strategy of your study:
- Maintain oversight regarding any delegated tasks and/or functions in order to ensure compliance with the risk-based QMS of the study
- Collect feedback from study staff in order to ensure ongoing effectiveness of risk control-measures
- Train study staff and communicate potential adaptations to risk control-measures
- Document all risk related activities, including any evaluation or rational for implemented/ adapted risk control-measures in the Risk Assessment Form (RAF) of your study
Mehr
Risk communication should be a 2-way process
Effective risk communication requires open and continuous exchange between all stakeholders.
As a SP-INV implement 2-way communication channels with:
- Site-INV(s) of participant study site(s)
- Subcontractors (e.g. partners, service providers such as CTU or CRO)
As a Site-INV:
- Provide ongoing relevant feedback to the SP-INV and site staff
- Ensure information flow through regular team meetings
- Clearly define responsibilities within implemented risk control procedures
- Discuss and define problem-solving strategies
To reach all potential stakeholders, applicable information and critical updates can be shared via newsletter or other structured communication methods
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R2) – see in particular guidelines
- 5.0 for Quality management
- 5.0.5 Risk communication
- 5.2.2 Addendum: Sponsor oversight
ISO 9001:2015 (access liable to costs) – see in particular section
- Quality Management Systems
Swiss Law
ClinO – see in particular article
- Art. 57a Reporting of serious adverse events